NASDAQ:FBIO - Fortress Biotech Stock Price, Forecast & News

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Fortress Biotech (NASDAQ:FBIO) posted its earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.22. The biopharmaceutical company earned $9.25 million during the quarter, compared to analyst estimates of $7.51 million. Fortress Biotech had a negative return on equity of 131.74% and a negative net margin of 143.08%. View Fortress Biotech's Earnings History.

Fortress Biotech is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Fortress Biotech.

3 analysts have issued 12 month price objectives for Fortress Biotech's shares. Their forecasts range from $4.00 to $19.00. On average, they expect Fortress Biotech's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 469.5% from the stock's current price. View Analyst Price Targets for Fortress Biotech.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech.

Media headlines about FBIO stock have been trending very negative recently, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Fortress Biotech earned a news impact score of -3.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Fortress Biotech.

Fortress Biotech saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,290,000 shares, a decrease of 7.9% from the October 31st total of 1,400,000 shares. Based on an average daily volume of 327,300 shares, the days-to-cover ratio is presently 3.9 days. Currently, 2.7% of the company's shares are short sold. View Fortress Biotech's Current Options Chain.

Some companies that are related to Fortress Biotech include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include TG Therapeutics (TGTX), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), ZIOPHARM Oncology (ZIOP), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Geron (GERN), T2 Biosystems (TTOO), AcelRx Pharmaceuticals (ACRX) and Novavax (NVAX).

Fortress Biotech's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.58%), FNY Investment Advisers LLC (0.29%), Shikiar Asset Management Inc. (0.26%), PVG Asset Management Corp (0.11%), State Street Corp (0.11%) and Rational Advisors LLC (0.11%). Company insiders that own Fortress Biotech stock include George Avgerinos and Robyn Hunter. View Institutional Ownership Trends for Fortress Biotech.

FBIO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and State Street Corp. View Insider Buying and Selling for Fortress Biotech.

FBIO stock was bought by a variety of institutional investors in the last quarter, including Shikiar Asset Management Inc., PVG Asset Management Corp, Rational Advisors LLC, FNY Investment Advisers LLC and Tower Research Capital LLC TRC. View Insider Buying and Selling for Fortress Biotech.

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FBIO stock can currently be purchased for approximately $1.99.

Fortress Biotech has a market capitalization of $140.85 million and generates $26.88 million in revenue each year. The biopharmaceutical company earns $-84,150,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe.View Additional Information About Fortress Biotech.

The official website for Fortress Biotech is http://www.fortressbiotech.com/.

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]